be 10988 has been researched along with Leukemia L 1210 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailly, C; Catrycke, MO; Dassonneville, L; Hénichart, JP; Houssin, R; Pfeiffer, B; Renard, P | 1 |
| Funaishi, K; Kawamura, K; Murai, T; Oka, H; Okanishi, M; Okura, A; Satoh, F; Shizuri, Y; Suda, H; Yoshinari, T | 1 |
2 other study(ies) available for be 10988 and Leukemia L 1210
| Article | Year |
|---|---|
Synthesis and cytotoxicity of analogues of the antibiotic BE 10988 inhibitors of DNA topoisomerase II.
Topics: Animals; Cell Division; DNA; Enzyme Inhibitors; Indoles; Inhibitory Concentration 50; Leukemia L1210; Mice; Quinones; Solubility; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 1999 |
A new topoisomerase-II inhibitor, BE-10988, produced by a streptomycete. I. Taxonomy, fermentation, isolation and characterization.
Topics: Animals; Antineoplastic Agents; Fermentation; Leukemia L1210; Streptomyces; Thiazoles; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1991 |